Application of Clinical Biomarkers for the Development of Multimodal Imaging Agents

临床生物标志物在多模态成像剂开发中的应用

• 批准号: 133440
• 金额: $ 8.69万
• 依托单位: PLATINA BIOMEDICAL TECHNOLOGIES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133440
• 关键词: Application; Clinical; Biomarkers; Development; Multimodal

"Incorrect assignment of cancer stage in advanced-cancer-patients is responsible for the incorrect choice of first-line cancer therapy leading to increased-mortality(1.5-2x) and lowered-survival (less than 12 months) in as-many-as 25% of all patients diagnosed with cancer in the UK.Contrast-enhanced MR and CT imaging are the most common imaging modalities for cancer imaging and staging across all treatment regimes. Current MR/CT imaging contrast imaging agents do not possess required specificity and sensitivity and therefore cannot distinguish between cancer sub-stages, resulting in an inaccurate and imprecise estimation of cancer stage.The project develops ""novel"" i.e. patient-specific, MR/CT imaging-sensitive and side-effects-free imaging agents. The imaging agents are composed of multifunctional nanoparticles and cancer biomarker targeting ligands. The nanoparticles are biologically compatible and capable of optimizing contrast in MR and CT imaging. Most importantly, the nanoparticle agents specifically bind to cancer cells, therefore, are required in 4-10x lower dosage relative to existing MR/CT imaging contrast agents to optimize tumour contrast, thus causing minimum inconvenience and adverse effects in patients.The imaging agents will not only reduce the time and frequency of patient's clinical visits but also reduce the overall cost of cancer treatment by increasing overall cancer treatment efficacy by minimizing revision surgeries, imaging sessions and related-inefficiencies. Therefore the personalized imaging agents will promote sustainable healthcare by enabling cancer patient's access to adequate and cost-effective healthcare."

“在英国，晚期癌症患者癌症分期的不正确分配是一线癌症治疗选择错误的原因，导致多达25%的癌症确诊患者死亡率增加（1.5-2倍）和生存率降低（不到12个月）。对比增强MR和CT成像是所有治疗方案中最常见的癌症成像和分期成像方式。目前的MR/CT成像造影剂不具备所需的特异性和敏感性，因此无法区分癌症的亚分期，导致对癌症分期的估计不准确和不精确。该项目开发了“新颖的”，即针对患者的、MR/CT成像敏感的、无副作用的显像剂。显像剂由多功能纳米颗粒和靶向癌症生物标志物配体组成。纳米颗粒具有生物相容性，能够优化MR和CT成像的对比度。最重要的是，纳米颗粒剂与癌细胞特异性结合，因此，相对于现有的MR/CT成像造影剂，需要低4-10倍的剂量来优化肿瘤造影剂，从而对患者造成最小的不便和不良影响。显像剂不仅可以减少患者临床就诊的时间和频率，还可以通过减少翻修手术、成像次数和相关低效率来提高整体癌症治疗效果，从而降低癌症治疗的总体成本。因此，个性化显像剂将促进可持续的医疗保健，使癌症患者能够获得充分和具有成本效益的医疗保健。”